Danaher Corporation (DHR)
Anchor Investment Management LLC Sells 4,317 Shares of Danaher Corporation $DHR
Anchor Investment Management LLC reduced its holdings in shares of Danaher Corporation (NYSE: DHR) by 48.3% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,614 shares of the conglomerate's stock after selling 4,317 shares during the period. Anchor Investment
Arrowstreet Capital Limited Partnership Boosts Stock Position in Danaher Corporation $DHR
Arrowstreet Capital Limited Partnership increased its stake in Danaher Corporation (NYSE: DHR) by 33.9% in the undefined quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,519,013 shares of the conglomerate's stock after purchasing an additional 891,210 shares during the quarter. Arrowstreet Capital Limited Partnership
Danaher Corporation (DHR) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Danaher Corporation (DHR) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Danaher's $9.9B Masimo Deal Marks One of 2026's Largest Medtech Buyouts
Danaher (NYSE: DHR) is acquiring Masimo (NASDAQ: MASI) for $9.9 billion in an all-cash deal that values the medical technology company at $180 per share.
Danaher to acquire Masimo in $9.9B all-cash deal
Danaher Corporation (NYSE:DHR) announced it has entered into a definitive agreement to acquire Masimo Corporation (NASDAQ: MASI) in an all-cash transaction valued at approximately $9.9 billion, as the life sciences and diagnostics company looks to expand its patient monitoring capabilities. Under the terms of the agreement, Danaher will acquire all outstanding Masimo common shares for $180 per share in cash.
Danaher closes in on nearly $10 billion deal for Masimo, FT reports
US healthcare manufacturer Danaher is closing in a nearly $10 billion deal to acquire medical technology company Masimo , the Financial Times reported on Monday, citing people familiar with the matter.
Danaher Stock Plunge Does Not Represent A Good Entry Point
Danaher Stock Plunge Does Not Represent A Good Entry Point
Danaher Q4 Earnings Beat Estimates, Life Sciences Sales Up Y/Y
DHR beats Q4 estimates as sales rise 4.5%, driven by strength across Life Sciences, Diagnostics and Biotech, and issued upbeat 2026 earnings guidance.
Danaher Corporation (DHR) Q4 2025 Earnings Call Transcript
Danaher Corporation (DHR) Q4 2025 Earnings Call Transcript
Compared to Estimates, Danaher (DHR) Q4 Earnings: A Look at Key Metrics
The headline numbers for Danaher (DHR) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Danaher (DHR) Beats Q4 Earnings and Revenue Estimates
Danaher (DHR) came out with quarterly earnings of $2.23 per share, beating the Zacks Consensus Estimate of $2.22 per share. This compares to earnings of $2.14 per share a year ago.
Danaher forecasts 2026 profit in line with estimates on pharma spending recovery
Life sciences firm Danaher Corp forecast annual profit largely in line with Wall Street estimates on Wednesday and beat fourth-quarter profit and revenue expectations, as improving conditions in the pharmaceutical market and reduced policy uncertainties offset weakness in academic research funding.
